Table 2:

Crude incidence rates of cardiovascular events by induction agent

	IL-2RA			ATG			AZM			None			Overall
	Number of events	Person-years^	IR	Number of events	Person-years^	IR	Number of events	Person-years^	IR	Number of events	Person-years^	IR	Number of events	Person-years^	IR
MI	440	62.8	7.01	385	57.7	6.67	60	10.5	5.70	492	72.4	6.79	1377	203.4	6.77
Cath	411	62.6	6.57	351	57.5	6.11	42	10.5	3.99	457	72.2	6.33	1261	202.8	6.22
CABG	98	63.6	1.54	67	58.3	1.15	5	10.6	0.47	100	73.3	1.36	270	205.8	1.31
CHF	1364	60.5	22.53	1187	55.9	21.23	188	10.3	18.18	1442	70.1	20.58	4181	196.8	21.24
AFib	583	62.6	9.31	475	57.5	8.25	81	10.5	7.70	619	72.2	8.57	1758	202.9	8.66
TIA	197	63.3	3.11	189	58.0	3.26	28	10.6	2.65	209	73.1	2.86	623	205.0	3.04
Stroke	367	63.2	5.81	365	57.8	6.32	58	10.5	5.51	418	72.8	5.74	1208	204.3	5.91
VTE	717	62.0	11.56	687	56.9	12.08	111	10.4	10.62	737	71.6	10.29	2252	201.0	11.20
Amputation	173	63.4	2.73	119	58.2	2.05	11	10.6	1.04	199	73.1	2.72	502	205.2	2.45
PVD	172	63.3	2.72	133	58.1	2.29	22	10.6	2.08	185	73.0	2.53	512	204.9	2.50
Any CVE	2426	57.2	42.42	2287	53.0	43.14	359	10.0	35.89	2587	66.1	39.11	7659	186.3	41.10
All-cause mortality	3034	84.3	35.97	2325	74.5	31.19	351	12.6	27.73	3438	97.3	35.34	9148	268.8	34.03
CVE-related mortality	447	84.3	5.30	333	74.5	4.47	50	12.6	3.95	516	97.3	5.30	1346	268.8	5.01

^*Unit for IR: (Cases/Person-years)*1,000

^{^}expressed in 1,000 person-years

AZM: alemtuzumab, ATG: anti-thymocyte globulin, AFib: atrial fibrillation, Cath: cardiac catheterization, CVE: cardiovascular event, CHF: congestive heart failure, CABG: coronary artery bypass graft, VTE: venous thromboembolism, IR: incidence rate, IL-2RA: IL-2 receptor antagonist, MI: myocardial ischemia, PVD: peripheral vascular disease, TIA: transient ischemic attack